CA2453198A1 - Quantification et production d'exosomes immunosuppresseurs - Google Patents

Quantification et production d'exosomes immunosuppresseurs Download PDF

Info

Publication number: CA2453198A1
Authority: CA; Canada
Prior art keywords: exosomes; antibody; exosome; cells; immune
Prior art date: 2004-01-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2453198

Other languages

English (en)

Inventor

Wei-Ping Min

Thomas Emanuel Ichim

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-07

Filing date

2004-01-07

Publication date

2005-07-07

2004-01-07 Application filed by Individual filed Critical Individual

2004-01-07 Priority to CA 2453198 priority Critical patent/CA2453198A1/fr

2005-07-07 Publication of CA2453198A1 publication Critical patent/CA2453198A1/fr

Status Abandoned legal-status Critical Current

Links

210000001808 exosome Anatomy 0.000 title claims abstract description 113
230000006028 immune-suppresssive effect Effects 0.000 title claims abstract description 21
238000011002 quantification Methods 0.000 title claims description 4
206010028980 Neoplasm Diseases 0.000 claims abstract description 56
238000000034 method Methods 0.000 claims abstract description 44
201000011510 cancer Diseases 0.000 claims abstract description 36
238000000746 purification Methods 0.000 claims abstract description 7
239000013060 biological fluid Substances 0.000 claims abstract description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 30
210000004027 cell Anatomy 0.000 claims description 30
230000006907 apoptotic process Effects 0.000 claims description 27
210000004443 dendritic cell Anatomy 0.000 claims description 18
239000000427 antigen Substances 0.000 claims description 17
102000036639 antigens Human genes 0.000 claims description 17
108091007433 antigens Proteins 0.000 claims description 17
230000008629 immune suppression Effects 0.000 claims description 14
210000002381 plasma Anatomy 0.000 claims description 12
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 10
238000010186 staining Methods 0.000 claims description 10
102000004169 proteins and genes Human genes 0.000 claims description 9
108090000623 proteins and genes Proteins 0.000 claims description 9
230000028993 immune response Effects 0.000 claims description 8
230000006698 induction Effects 0.000 claims description 8
210000002966 serum Anatomy 0.000 claims description 7
102000004121 Annexin A5 Human genes 0.000 claims description 6
108090000672 Annexin A5 Proteins 0.000 claims description 6
102000004127 Cytokines Human genes 0.000 claims description 6
108090000695 Cytokines Proteins 0.000 claims description 6
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 6
108010024164 HLA-G Antigens Proteins 0.000 claims description 6
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 6
230000004913 activation Effects 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
239000012530 fluid Substances 0.000 claims description 6
230000001965 increasing effect Effects 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 6
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
238000001514 detection method Methods 0.000 claims description 5
238000000684 flow cytometry Methods 0.000 claims description 5
230000035755 proliferation Effects 0.000 claims description 5
238000001890 transfection Methods 0.000 claims description 5
108010039471 Fas Ligand Protein Proteins 0.000 claims description 4
102000003814 Interleukin-10 Human genes 0.000 claims description 4
108090000174 Interleukin-10 Proteins 0.000 claims description 4
102000003816 Interleukin-13 Human genes 0.000 claims description 4
108090000176 Interleukin-13 Proteins 0.000 claims description 4
230000033540 T cell apoptotic process Effects 0.000 claims description 4
210000004369 blood Anatomy 0.000 claims description 4
239000008280 blood Substances 0.000 claims description 4
230000003247 decreasing effect Effects 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
230000028327 secretion Effects 0.000 claims description 4
230000006044 T cell activation Effects 0.000 claims description 3
238000013459 approach Methods 0.000 claims description 3
230000016396 cytokine production Effects 0.000 claims description 3
230000004936 stimulating effect Effects 0.000 claims description 3
210000003719 b-lymphocyte Anatomy 0.000 claims description 2
238000003501 co-culture Methods 0.000 claims description 2
210000004698 lymphocyte Anatomy 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
239000008188 pellet Substances 0.000 claims description 2
239000006228 supernatant Substances 0.000 claims description 2
210000000612 antigen-presenting cell Anatomy 0.000 claims 12
238000005406 washing Methods 0.000 claims 4
102000004388 Interleukin-4 Human genes 0.000 claims 3
108090000978 Interleukin-4 Proteins 0.000 claims 3
102100027221 CD81 antigen Human genes 0.000 claims 2
102100027217 CD82 antigen Human genes 0.000 claims 2
102100037904 CD9 antigen Human genes 0.000 claims 2
101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 2
101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims 2
101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 2
102000003945 NF-kappa B Human genes 0.000 claims 2
108010057466 NF-kappa B Proteins 0.000 claims 2
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
150000005829 chemical entities Chemical class 0.000 claims 2
238000000605 extraction Methods 0.000 claims 2
239000003550 marker Substances 0.000 claims 2
230000008685 targeting Effects 0.000 claims 2
102000009027 Albumins Human genes 0.000 claims 1
108010088751 Albumins Proteins 0.000 claims 1
101150013553 CD40 gene Proteins 0.000 claims 1
101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
102100033486 Lymphocyte antigen 75 Human genes 0.000 claims 1
101710157884 Lymphocyte antigen 75 Proteins 0.000 claims 1
102000005886 STAT4 Transcription Factor Human genes 0.000 claims 1
108010019992 STAT4 Transcription Factor Proteins 0.000 claims 1
102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 claims 1
108020004459 Small interfering RNA Proteins 0.000 claims 1
101710124574 Synaptotagmin-1 Proteins 0.000 claims 1
102100036840 T-box transcription factor TBX21 Human genes 0.000 claims 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
230000004075 alteration Effects 0.000 claims 1
239000011324 bead Substances 0.000 claims 1
230000003833 cell viability Effects 0.000 claims 1
230000001461 cytolytic effect Effects 0.000 claims 1
231100000433 cytotoxic Toxicity 0.000 claims 1
230000001472 cytotoxic effect Effects 0.000 claims 1
102000004114 interleukin 20 Human genes 0.000 claims 1
108090000681 interleukin 20 Proteins 0.000 claims 1
229940028885 interleukin-4 Drugs 0.000 claims 1
239000003446 ligand Substances 0.000 claims 1
210000002540 macrophage Anatomy 0.000 claims 1
230000002438 mitochondrial effect Effects 0.000 claims 1
210000000581 natural killer T-cell Anatomy 0.000 claims 1
239000002504 physiological saline solution Substances 0.000 claims 1
210000003296 saliva Anatomy 0.000 claims 1
239000004055 small Interfering RNA Substances 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
210000004243 sweat Anatomy 0.000 claims 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
210000002700 urine Anatomy 0.000 claims 1
230000001900 immune effect Effects 0.000 abstract description 9
230000001225 therapeutic effect Effects 0.000 abstract description 3
238000010324 immunological assay Methods 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 description 12
208000000236 Prostatic Neoplasms Diseases 0.000 description 12
241000282414 Homo sapiens Species 0.000 description 11
238000005119 centrifugation Methods 0.000 description 9
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
230000001419 dependent effect Effects 0.000 description 6
210000002865 immune cell Anatomy 0.000 description 6
108091008874 T cell receptors Proteins 0.000 description 5
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
229940092253 ovalbumin Drugs 0.000 description 5
230000004044 response Effects 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
230000034994 death Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
229920001481 poly(stearyl methacrylate) Polymers 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
206010003445 Ascites Diseases 0.000 description 2
238000009010 Bradford assay Methods 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000037417 hyperactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000036962 time dependent Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
241001161492 Exosoma Species 0.000 description 1
101150089023 FASLG gene Proteins 0.000 description 1
244000182067 Fraxinus ornus Species 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
125000000635 L-ornithyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940126587 biotherapeutics Drugs 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000004940 costimulation Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
108010052621 fas Receptor Proteins 0.000 description 1
102000018823 fas Receptor Human genes 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000005965 immune activity Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
238000002826 magnetic-activated cell sorting Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000004091 panning Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
239000012096 transfection reagent Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA 2453198 2004-01-07 2004-01-07 Quantification et production d'exosomes immunosuppresseurs Abandoned CA2453198A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2453198 CA2453198A1 (fr)	2004-01-07	2004-01-07	Quantification et production d'exosomes immunosuppresseurs

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2453198 CA2453198A1 (fr)	2004-01-07	2004-01-07	Quantification et production d'exosomes immunosuppresseurs

Publications (1)

Publication Number	Publication Date
CA2453198A1 true CA2453198A1 (fr)	2005-07-07

Family

ID=34716035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2453198 Abandoned CA2453198A1 (fr)	2004-01-07	2004-01-07	Quantification et production d'exosomes immunosuppresseurs

Country Status (1)

Country	Link
CA (1)	CA2453198A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007088537A3 (fr) *	2006-01-31	2007-10-25	Medical Res Fund Of Tel Aviv S	Procédés et trousses pour la détection précoce du cancer ou d'une prédisposition au cancer
WO2007103572A3 (fr) *	2006-03-09	2008-09-12	Aethlon Medical Inc	Enlèvement extracorporel de particules microvésiculaires
WO2009092386A2 (fr)	2008-01-25	2009-07-30	Hansabiomed Oü	Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
WO2009100029A1 (fr) *	2008-02-01	2009-08-13	The General Hospital Corporation	Utilisation de microvésicules dans le diagnostic, le pronostic et le traitement de maladies et d’affections médicales
GB2463401A (en) *	2008-11-12	2010-03-17	Caris Mpi Inc	Diagnostic methods using exosomes
US7888035B2 (en)	2008-10-30	2011-02-15	Caris Mpi, Inc.	Methods for assessing RNA patterns
US9128101B2 (en)	2010-03-01	2015-09-08	Caris Life Sciences Switzerland Holdings Gmbh	Biomarkers for theranostics
US9469876B2 (en)	2010-04-06	2016-10-18	Caris Life Sciences Switzerland Holdings Gmbh	Circulating biomarkers for metastatic prostate cancer
US20170143812A1 (en) *	2015-11-20	2017-05-25	Therapeutic Solutions International, Inc.	Exosome mediated innate and adaptive immune stimulation for treatment of cancer
CN106814187A (zh) *	2017-01-16	2017-06-09	杭州联川基因诊断技术有限公司	外周游离外泌体在制备液态活检肿瘤诊断试剂中的应用
US10022483B2 (en)	2003-01-17	2018-07-17	Aethlon Medical, Inc.	Method for removal of viruses from blood by lectin affinity hemodialysis
EP3299816A4 (fr) *	2015-05-20	2018-10-03	JSR Corporation	Procédé de séparation, procédé de détection, procédé de mesure de signal, procédé de détermination de maladie, procédé d'évaluation de l'efficacité d'un médicament, kit, composition de liquide et diluant d'échantillon
US10407728B2 (en)	2009-09-09	2019-09-10	The General Hospital Corporation	Use of microvesicles in analyzing nucleic acid profiles
US10532128B2 (en)	2015-11-18	2020-01-14	Viera Bioscience, Inc.	Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
US10793914B2 (en)	2010-08-31	2020-10-06	The General Hospital Corporation	Cancer-related biological materials in microvesicles
US10988755B2 (en)	2010-11-10	2021-04-27	Exosome Diagnostics, Inc.	Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
US11155874B2 (en)	2009-09-09	2021-10-26	The General Hospital Corporation	Use of microvesicles in analyzing mutations
CN114891723A (zh) *	2022-06-30	2022-08-12	北京三元食品股份有限公司	一种乳源外泌体及提取方法
CN117866896A (zh) *	2024-01-12	2024-04-12	蚌埠医学院	一种Mtb-HAg诱导的M2b型巨噬细胞来源外泌体及其制备方法和应用

2004
- 2004-01-07 CA CA 2453198 patent/CA2453198A1/fr not_active Abandoned

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10022483B2 (en)	2003-01-17	2018-07-17	Aethlon Medical, Inc.	Method for removal of viruses from blood by lectin affinity hemodialysis
WO2007088537A3 (fr) *	2006-01-31	2007-10-25	Medical Res Fund Of Tel Aviv S	Procédés et trousses pour la détection précoce du cancer ou d'une prédisposition au cancer
US9394569B2 (en)	2006-01-31	2016-07-19	The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center	Methods and kits for early detection of cancer or predisposition thereto
WO2007103572A3 (fr) *	2006-03-09	2008-09-12	Aethlon Medical Inc	Enlèvement extracorporel de particules microvésiculaires
EP3517151A1 (fr) *	2006-03-09	2019-07-31	Aethlon Medical, Inc.	Enlèvement extracorporel de particules microvésiculaires
US9707333B2 (en)	2006-03-09	2017-07-18	Aethlon Medical, Inc.	Extracorporeal removal of microvesicular particles
US9364601B2 (en)	2006-03-09	2016-06-14	Aethlon Medical, Inc.	Extracorporeal removal of microvesicular particles
US8288172B2 (en)	2006-03-09	2012-10-16	Aethlon Medical, Inc.	Extracorporeal removal of microvesicular particles
CN102317778A (zh) *	2008-01-25	2012-01-11	汉萨生物医药公司	测定和表征人体液中微泡的新方法
WO2009092386A3 (fr) *	2008-01-25	2009-09-17	Hansabiomed Oü	Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
WO2009092386A2 (fr)	2008-01-25	2009-07-30	Hansabiomed Oü	Nouveau procédé de mesure et de caractérisation de microvésicules dans des liquides organiques humain
RU2520741C2 (ru) *	2008-01-25	2014-06-27	Хансабиомед Ою	Новый способ количественного определения и охарактеризования микровезикул в жидкостях организма человека
AU2009207927B2 (en) *	2008-01-25	2015-04-09	Exosomics S.p.A.	A new method to measure and characterize microvesicles in the human body fluids
CN102317778B (zh) *	2008-01-25	2015-05-13	汉萨生物医药公司	测定和表征人体液中微泡的新方法
EP2604704B1 (fr) *	2008-02-01	2018-10-03	The General Hospital Corporation	Utilisation de microvésicules pour le diagnostic et le pronostic de la tumeur cérébrale
WO2009100029A1 (fr) *	2008-02-01	2009-08-13	The General Hospital Corporation	Utilisation de microvésicules dans le diagnostic, le pronostic et le traitement de maladies et d’affections médicales
US7888035B2 (en)	2008-10-30	2011-02-15	Caris Mpi, Inc.	Methods for assessing RNA patterns
GB2463401B (en) *	2008-11-12	2014-01-29	Caris Life Sciences Luxembourg Holdings S A R L	Characterizing prostate disorders by analysis of microvesicles
GB2463401A (en) *	2008-11-12	2010-03-17	Caris Mpi Inc	Diagnostic methods using exosomes
US7897356B2 (en)	2008-11-12	2011-03-01	Caris Life Sciences	Methods and systems of using exosomes for determining phenotypes
US11519036B2 (en)	2009-09-09	2022-12-06	The General Hospital Corporation	Use of microvesicles in analyzing nucleic acid profiles
US11155874B2 (en)	2009-09-09	2021-10-26	The General Hospital Corporation	Use of microvesicles in analyzing mutations
US10407728B2 (en)	2009-09-09	2019-09-10	The General Hospital Corporation	Use of microvesicles in analyzing nucleic acid profiles
US9128101B2 (en)	2010-03-01	2015-09-08	Caris Life Sciences Switzerland Holdings Gmbh	Biomarkers for theranostics
US9469876B2 (en)	2010-04-06	2016-10-18	Caris Life Sciences Switzerland Holdings Gmbh	Circulating biomarkers for metastatic prostate cancer
US10793914B2 (en)	2010-08-31	2020-10-06	The General Hospital Corporation	Cancer-related biological materials in microvesicles
US12312582B2 (en)	2010-11-10	2025-05-27	Exosome Diagnostics, Inc.	Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
US10988755B2 (en)	2010-11-10	2021-04-27	Exosome Diagnostics, Inc.	Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
EP3299816A4 (fr) *	2015-05-20	2018-10-03	JSR Corporation	Procédé de séparation, procédé de détection, procédé de mesure de signal, procédé de détermination de maladie, procédé d'évaluation de l'efficacité d'un médicament, kit, composition de liquide et diluant d'échantillon
US10532128B2 (en)	2015-11-18	2020-01-14	Viera Bioscience, Inc.	Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
US20170143812A1 (en) *	2015-11-20	2017-05-25	Therapeutic Solutions International, Inc.	Exosome mediated innate and adaptive immune stimulation for treatment of cancer
CN106814187B (zh) *	2017-01-16	2018-11-09	杭州联川基因诊断技术有限公司	外周游离外泌体在制备液态活检肿瘤诊断试剂中的应用
CN106814187A (zh) *	2017-01-16	2017-06-09	杭州联川基因诊断技术有限公司	外周游离外泌体在制备液态活检肿瘤诊断试剂中的应用
CN114891723A (zh) *	2022-06-30	2022-08-12	北京三元食品股份有限公司	一种乳源外泌体及提取方法
CN117866896A (zh) *	2024-01-12	2024-04-12	蚌埠医学院	一种Mtb-HAg诱导的M2b型巨噬细胞来源外泌体及其制备方法和应用

Publication	Publication Date	Title
CA2453198A1 (fr)	2005-07-07	Quantification et production d'exosomes immunosuppresseurs
Pedroza-Gonzalez et al.	2011	Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Wong et al.	2013	IL-18–primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment
US20210017493A1 (en)	2021-01-21	Method of enhancing persistence of adoptively infused t cells
Brimnes et al.	2006	Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma
Baur et al.	2013	Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg
Rodrigues et al.	2016	Tolerogenic IDO+ dendritic cells are induced by PD-1-expressing mast cells
US8097242B2 (en)	2012-01-17	Target CA125 peptides for cancer immunotherapy
Du et al.	2022	Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Xie et al.	2020	Complement-activated interferon-γ–primed human endothelium transpresents interleukin-15 to CD8+ T cells
WO2009097119A2 (fr)	2009-08-06	Identification de lymphocytes cd8+ qui ont une expression élevée de cd161 (cd161hi) et/ou de il18rα(alpha) (il18rα(alpha)hi) et qui ont une capacité d'écoulement de médicament rapide
US11612644B2 (en)	2023-03-28	Cell population for use in treating cancer
Ghorbaninezhad et al.	2022	CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro
Ogden et al.	2006	Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas
Wu et al.	2021	Inhibition of iNKT cells by the HLA-G-ILT2 checkpoint and poor stimulation by HLA-G-expressing tolerogenic DC
JP2022543026A (ja)	2022-10-07	Ｎｋ細胞を評価するためのシステム及び方法
Figueroa‐Vega et al.	2006	Phenotypic analysis of IL‐10‐treated, monocyte‐derived dendritic cells in patients with systemic lupus erythematosus
US20070128670A1 (en)	2007-06-07	Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof
JPWO2005094886A1 (ja)	2008-02-14	Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
CN114645091B (zh)	2025-06-17	Rgs1抑制剂在制备乳腺癌肿瘤浸润性淋巴细胞治疗药物中的用途
Radej et al.	2015	Immunomodelling characteristics of mature dendritic cells stimulated by colon cancer cells lysates
TW202331254A (zh)	2023-08-01	癌處置的方法
Lee et al.	2021	Peripheral immune tolerance by prolactin-induced protein originated from human invariant natural killer T cells
Lee et al.	2010	Induction of 90K-specific cytotoxic T lymphocytes for colon cancer immunotherapy
Piapi	2017	Characterisation of CD3-enhanced gene-modified CD4+ T cells for cancer immunotherapy

Legal Events

Date	Code	Title	Description
2007-01-08	FZDE	Dead